Bristol-Myers Squibb Co (MEX:BMY) Total Liabilities : MXN1,505,717 Mil (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Bristol-Myers Squibb Co Total Liabilities?

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Sep. 2024 was MXN1,505,717 Mil.

Bristol-Myers Squibb Co's quarterly Total Liabilities increased from Mar. 2024 (MXN1,368,908.90 Mil) to Jun. 2024 (MXN1,421,218.63 Mil) and increased from Jun. 2024 (MXN1,421,218.63 Mil) to Sep. 2024 (MXN1,505,717.24 Mil).

Bristol-Myers Squibb Co's annual Total Liabilities declined from Dec. 2021 (MXN1,503,840.31 Mil) to Dec. 2022 (MXN1,280,926.19 Mil) and declined from Dec. 2022 (MXN1,280,926.19 Mil) to Dec. 2023 (MXN1,114,766.76 Mil).

Bristol-Myers Squibb Co Total Liabilities Historical Data

The historical data trend for Bristol-Myers Squibb Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Total Liabilities Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,475,719.56

1,603,275.31

1,503,840.31

1,280,926.19

1,114,766.76

Bristol-Myers Squibb Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,083,472.81	1,114,766.76	1,368,908.90	1,421,218.63	1,505,717.24

Bristol-Myers Squibb Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bristol-Myers Squibb Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	377880.709	+	(648127.711	+	62533.129
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	18077.574	+	8147.639)
	=	1,114,767

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1615252.464	-	500485.702
	=	1,114,767

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	445749.012	+	(987606.378	+	40837.682
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	22722.606	+	8801.564)
	=	1,505,717

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	1844390.402	-	338673.16
	=	1,505,717

Bristol-Myers Squibb Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (MEX:BMY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.